BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 25318587)

  • 1. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
    Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
    Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
    Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
    World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
    Tabouret E; Bequet C; Denicola├» E; Barri├ę M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
    Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
    Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
    Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
    Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
    Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic PXA in adults: case series with clinicopathologic and molecular features.
    Schmidt Y; Kleinschmidt-DeMasters BK; Aisner DL; Lillehei KO; Damek D
    J Neurooncol; 2013 Jan; 111(1):59-69. PubMed ID: 23096133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
    Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
    Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
    Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
    PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group.
    Ono T; Sasajima T; Shimizu H; Natsumeda M; Kanamori M; Asano K; Beppu T; Matsuda K; Ichikawa M; Fujii Y; Ohkuma H; Ogasawara K; Sonoda Y; Saito K; Nobusawa S; Nakazato Y; Kitanaka C; Kayama T; Tominaga T;
    Neurol Med Chir (Tokyo); 2020 Nov; 60(11):543-552. PubMed ID: 33071274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
    Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
    Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
    Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
    J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma.
    Zhang H; Ma XJ; Xiang XP; Wang QY; Tang JL; Yu XY; Xu JH
    Curr Oncol; 2023 Feb; 30(2):2405-2416. PubMed ID: 36826144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?
    Vaubel R; Zschernack V; Tran QT; Jenkins S; Caron A; Milosevic D; Smadbeck J; Vasmatzis G; Kandels D; Gnekow A; Kramm C; Jenkins R; Kipp BR; Rodriguez FJ; Orr BA; Pietsch T; Giannini C
    Brain Pathol; 2021 Jan; 31(1):20-32. PubMed ID: 32619305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
    Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA
    Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
    Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
    J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [BRAF V600E mutation and clinicopathologic characteristics in 250 cases of brain tumors associated with epilepsy].
    Qi XL; Yao K; Duan ZJ; Bian Y; Ma Z; Piao YS; Gong LP
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):664-670. PubMed ID: 30220118
    [No Abstract]   [Full Text] [Related]  

  • 17. [Epithelioid glioblastoma with BRAF V600E mutation: a clinicopathological and molecular study].
    Zheng LM; Gong J; Zou Y; Zhang MN; Yu TP; Hou J; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):229-235. PubMed ID: 33677887
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.
    Kata K; Rodriguez-Quintero JC; Arevalo OD; Zhang JJ; Bhattacharjee MB; Ware C; Dono A; Riascos-Castaneda R; Tandon N; Blanco A; Esquenazi Y; Ballester LY; Amsbaugh M; Day AL; Zhu JJ
    J Natl Compr Canc Netw; 2022 Nov; 20(11):1193-1202.e6. PubMed ID: 36351333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.
    Lohkamp LN; Schinz M; Gehlhaar C; Guse K; Thomale UW; Vajkoczy P; Heppner FL; Koch A
    PLoS One; 2016; 11(6):e0156422. PubMed ID: 27253461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.